Recombinant Human Large neutral amino acids transporter small subunit 1 (SLC7A5), partial

^{In
Stock}

中文名稱：

人SLC7A5重組蛋白
貨號：

CSB-EP021717HU
說明書：

MSDS Datasheet
規(guī)格：

￥1836
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

SLC7A5
Uniprot No.：

Q01650
別名：

4F2 light chain CD98 light chain Integral membrane protein E16 L-type amino acid transporter 1 Solute carrier family 7 member 5 y+ system cationic amino acid transporter
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

E.coli
分子量：

19.7 kDa
表達區(qū)域：

16-50aa
氨基酸序列

AEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNI
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

N-terminal?10xHis-SUMO-tagged?and?C-terminal?Myc-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 662
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評價

靶點詳情

功能：

The heterodimer with SLC3A2 functions as sodium-independent, high-affinity transporter that mediates uptake of large neutral amino acids such as phenylalanine, tyrosine, L-DOPA, leucine, histidine, methionine and tryptophan. Functions as an amino acid exchanger. May play a role in the transport of L-DOPA across the blood-brain barrier. May act as the major transporter of tyrosine in fibroblasts (Probable). May mediate blood-to-retina L-leucine transport across the inner blood-retinal barrier. Can mediate the transport of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane. When associated with LAPTM4B, the heterodimer formed by SLC3A2 and SLC7A5 is recruited to lysosomes to promote leucine uptake into these organelles, and thereby mediates mTORC1 activation. Involved in the uptake of toxic methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the membrane.; (Microbial infection) In case of hepatitis C virus/HCV infection, the complex formed by SLC3A2 and SLC7A5/LAT1 plays a role in HCV propagation by facilitating viral entry into host cell and increasing L-leucine uptake-mediated mTORC1 signaling activation, thereby contributing to HCV-mediated pathogenesis.
基因功能參考文獻：
1. L-type amino acid transporter 1 (LAT1) is overexpressed in the synovium of rheumatoid arthritis (RA). Suppressing the LAT1 genes by using RNA interference and the LAT inhibitor, BCH reduces the phosphorylation of mTOR and its downstream target 4EBP1, radiolabeled leucine uptake, and migration of RA FLS. Treatment of cells with Interleukin-17 stimulates the expression of LAT1. PMID: 29198077
2. Data suggest that amino acid uptake via ASCT2/SLC1A5 is required for cell proliferation/tumor growth independently of LAT1/SLC7A5; in part, these studies were conducted in lung and colon adenocarcinoma cell lines and involved gene knockout techniques. (ASCT2/SLC1A5 = solute carrier family-1 member-5; LAT1/SLC7A5 = solute carrier family-7 member-5) PMID: 29326164
3. review the upstream regulators of LAT1 and the downstream effects caused by the overexpression of LAT1 in cancer cells. PMID: 30103560
4. These preclinical results show that LAT1 inhibition is a novel therapeutic approach in the context of thyroid cancers, and more interestingly in untreatable thyroid cancers. PMID: 30241549
5. These data collectively establish that in an in vitro context, human epithelial and mesenchymal hepatocellular carcinoma cell lines adapt to ASCT2 or LAT1 knockout. PMID: 30029480
6. SLC7A5 gene plays a role in promoting tumor development, which is regulated by the TGF-beta1 signaling pathway. PMID: 28626091
7. LAT1 is located close to the plasma membrane in skeletal muscle fibres and in close proximity to the microvasculature. Note a greater immunoreactivity of this protein in the sarcoplasm of type II fibres, potentially supporting the greater anabolic potential in these fibres. PMID: 29278358
8. LAT1-NAD+-SIRT1 signaling is activated in tumor tissues of patients with non-small cell lung cancer; NAD+ synthesis regulates the SIRT1-FOXO1 apoptotic pathway in response to NQO1 PMID: 27566573
9. Thus, our results indicated that lncRNA-PVT1-5 may function as a competing endogenous RNA (ceRNA) for miR-126 to promote cell proliferation by regulating the miR-126/SLC7A5 pathway, suggesting that lncRNA-PVT1-5 plays a crucial role in lung cancer progression and lncRNA-PVT1-5/miR-126/SLC7A5 regulatory network may shed light on tumorigenesis in lung cancer. PMID: 29277611
10. Study showed that a positive [18F] FDOPA uptake in PET was associated with a minimal threshold of LAT1 expression, but did not find a linear correlation between intensity of [18F] FDOPA uptake and level of LAT1 expression. PMID: 28937983
11. this study shows that IL-2-induced expression of CD98 is a prerequisite for NKG2D-mediated activation of NK cells PMID: 28784848
12. These results demonstrate a novel fundamental role of LAT1 to support the protein expression of 4F2hc via a chaperone-like function in chorionic trophoblasts. PMID: 28320871
13. MTA1 expression was positively correlated with LAT1 (p=0.013) and CD34 (p=0.034) expression, but not with Ki-67 (p=0.078). MTA1 shows promise as a diagnostic and prognostic marker in esophageal cancer, and we anticipate that the gene will also prove to be a good therapeutic target. PMID: 28739699
14. LAT1 overexpression was common in Brain Metastases and was specific for Brain Metastases as compared to healthy brain. These results could explain the specific Brain Metastases uptake on PET-AA. PMID: 27276226
15. LAT1 and LAT2 were overexpressed in both pheochromocytoma and medullary thyroid carcinoma by comparison with normal tissues. PMID: 27224648
16. he findings in this study indicate a regulation relationship between CRKL and SLC7A5, and provide useful evidence for gastric cancer therapeutic strategies. PMID: 27846244
17. Study shows that the solute carrier transporter 7a5 (SLC7A5), a large neutral amino acid transporter localized at the blood brain barrier (BBB), has an essential role in maintaining normal levels of brain branched-chain amino acids; also identified several patients with autistic traits and motor delay carrying deleterious homozygous mutations in the SLC7A5 gene. PMID: 27912058
18. The LAT1 isoform was confirmed as the major tyrosine transporter in patients with schizophrenia. However, the kinetic parameters (maximal transport capacity, affinity of the binding sites, and diffusion constant of tyrosine transport through the LAT1 isoform) did not differ between patients with schizophrenia and controls. PMID: 28190014
19. Expression levels of CD98 and beta1-integrin-A (the activated form of beta1-integrin) were significantly increased in hepatocellular carcinoma (HCC) tissues relative to those of normal liver tissues. PMID: 27834933
20. Authors demonstrate that LAT1 is a critical transporter for human thymic carcinoma cells. LAT1 was strongly expressed in human thymic carcinoma tissues. PMID: 27567475
21. Our study demonstrates that suppression of l-type amino acid transporter-1 activity using JPH203 might be used as a new therapeutic strategy for cholangiocarcinoma treatment. PMID: 28347255
22. This study shows the utility of (18)F-FBPA as a tumor-specific probe of LAT1 with low accumulation in the inflammatory lesions. PMID: 27550420
23. the discovery of CD98 protein on the cell surface of the majority of malignant melanomas, is reported. PMID: 26850337
24. High SLC7A5 expression is associated with myelodysplastic syndrome. PMID: 26657287
25. LAT1 is not a leucine sensor. PMID: 26724922
26. Proliferation of breast cancer cells is dependent on the expression of both LAT1 and AHR. PMID: 26944194
27. CD98 promotes cell spreading and tumorigenicity by triggering integrin clustering and enhancing cell adhesion to the extracellular matrix. PMID: 26437640
28. Propose regulation of placental SNAT2/LAT1 ubiquitination by mTORC1 and Nedd4-2. PMID: 26608079
29. Independently of Gleason score, aberrant overexpression of LAT1 in prostatic adenocarcinoma could predict LP under EM. Although prostate biopsy samples are small, LAT1 may be a novel prognostic biomarker of LP. PMID: 25835180
30. LAT1 is the transport competent unit of the LAT1/CD98 heterodimeric amino acid transporter. PMID: 26256001
31. LAT1 can serve as a significant prognostic factor to predict a poor outcome and it may therefore play an important role in the aggressiveness of cutaneous melanoma. PMID: 26237765
32. exposure to diesel exhaust particle extract induces functional overexpression of the amino acid transporter LAT1/CD98hc in lung cells PMID: 26621329
33. LAPTM4b recruits LAT1-4F2hc to lysosomes, leading to uptake of leucine into lysosomes. PMID: 25998567
34. These results suggest that LAT1 expression is associated with disease progression in gastric carcinoma. PMID: 25908107
35. LAT1 and LAT2 are present and functional in the syncytiotrophoblast MVM, whereas LAT2 is also expressed in the BM and in the fetal capillary endothelium. PMID: 26050671
36. miR-126 plays a pivotal role in GC (gastric cancer) suppressing the process of GC cell, and this function is at least partly taken to implement by miR-126s's post-transcriptional effect on LAT-1. PMID: 26054677
37. shRNA-mediated knockdown of Lat1 results in tumor growth inhibition and points to Lat1 as a potential therapeutic target. PMID: 25979827
38. data, therefore, suggest that FET is trapped within cells due to the asymmetry of its intra- and extracellular recognition by LAT1. PMID: 25385314
39. Metabolic changes accompanying activation of T cells must occur simultaneously with the reorganization of LAT1 and other transporters that are capable of providing sufficient nutrients to the cell. (Review) PMID: 25597310
40. CAP-D3 down-regulates transcription of genes that encode amino acid transporters (SLC7A5 and SLC3A2) to promote bacterial autophagy by colon epithelial cells. PMID: 25701737
41. aberrant overexpression of LAT1 in bile duct adenocarcinoma predicts poor prognosis, suggesting that LAT1 may be a potential target of anticancer therapy. PMID: 24890221
42. Seven SNPs in SLC7A5 and 20 in SLC7A8 were genotyped. Multiple analyses indicated that 1 SNP in the first intron of SLC7A5, rs4240803, was significantly associated with TPN use. PMID: 24704384
43. CD147 and CD98 might play important roles in cyclophilin-induced cell migration. PMID: 25089027
44. The study shows that the expression of LAT1 on myeloma cells is significantly associated with high proliferative activity as well as poor prognosis in patients with newly diagnosed multiple myeloma. PMID: 25220100
45. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression. PMID: 24694899
46. LAT1 and its associated protein, 4F2hc, are up-regulated and miR-7 expression was regulated by LAT1. PMID: 24726839
47. Polymorphisms of the LAT1 gene, there was no evidence for either allelic and/or genotypic association with the risk of NSCL/P in the Polish population. PMID: 24606907
48. Studied the clinicopathological significance of LAT1 expression in adenoid cystic carcinoma (ACC). PMID: 23516127
49. LAT1 was expressed in gonad tissues and several kinds of cells having special functions, as well as being discovered to be an aspect of oncofetal protein. PMID: 23824658
50. LAT-1 may function as an oncogene in gastric cancer. PMID: 23809372
顯示更多

收起更多
亞細胞定位：

Apical cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein. Lysosome membrane; Multi-pass membrane protein.
蛋白家族：

Amino acid-polyamine-organocation (APC) superfamily, L-type amino acid transporter (LAT) (TC 2.A.3.8) family
組織特異性：

Detected in placenta, in the syncytiotrophoblast layer (at protein level). Expressed abundantly in adult lung, liver, brain, skeletal muscle, placenta, bone marrow, testis, resting lymphocytes and monocytes, and in fetal liver. Weaker expression in thymus
數(shù)據(jù)庫鏈接：

HGNC: 11063

OMIM: 600182

KEGG: hsa:8140

STRING: 9606.ENSP00000261622

UniGene: Hs.513797